2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow Rebiotix Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS) RBX2660 - Clostridium Difficile Infection, Infection | Phase 3 | Completed | Rebiotix Inc. | 793 | 2019-07-30 | 2024-08-07 |
| Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3) RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence) - Clostridium Difficile Infection (CDI) | Phase 3 | Completed | Rebiotix Inc. | 320 | 2017-07-31 | 2024-07-10 |
Clostridium Infections (2) · Diarrhea (2) · Enterocolitis, Pseudomembranous (2) · Communicable Diseases (1) · Infections (1)
Saline Solution (1) · Single Person (1)
Canada (2) · United States (2)
Teena Chopra, M.D., M.P.H. (2)
PMID 41245385, PMID 42286373, PMID 36287379, PMID 37564743, PMID 38236515, PMID 39172632, PMID 39180326, PMID 40177588, PMID 40552763, PMID 40672762, PMID 40784972, PMID 41115624, PMID 41653256, PMID 42840322